Odylia Therapeutics Marks Rare Disease Day with Focus on Funding & Collaboration

Odylia Therapeutics (Odylia) a nonprofit biotechnology company dedicated to expediting drug development for rare diseases, hosted a Rare Disease Day event ...

April 11, 2025 | Friday | News
AbbVie’s RINVOQ® Becomes First Oral JAK Inhibitor Approved in EU for Giant Cell Arteritis

AbbVie announced that the European Commission (EC) granted marketing authorization to RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment ...

April 10, 2025 | Thursday | News
FDA Approves Opdivo® Plus Yervoy® as First-Line Treatment for MSI-H/dMMR Metastatic Colorectal Cancer

 Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy®...

April 10, 2025 | Thursday | News
Idorsia’s Aprocitentan Demonstrates Efficacy in African American Patients with Resistant Hypertension

Idorsia Ltd  announced the publication of "Aprocitentan for Blood Pressure Reduction in Black Patients” in the April edition of Hypertensio...

April 10, 2025 | Thursday | News
Assembly Biosciences Showcases Promising HSV Treatment Data at ESCMID 2025

Assembly Biosciences, Inc., a biotechnology company developing innovative therapeutics targeting serious viral diseases,  announced data from its herp...

April 10, 2025 | Thursday | News
Science 37 Achieves Second Successful FDA Inspection, Reaffirming Commitment to High-Quality Clinical Trials

Science 37, a leader in enhancing patient access to clinical trials, announced the successful completion of its second FDA inspection, reaffirming the qual...

April 10, 2025 | Thursday | News
Serina Therapeutics Raises $5M to Advance Novel Parkinson’s Therapy Toward Phase 1 Trial

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform&tra...

April 09, 2025 | Wednesday | News
China’s Telitacicept Sets New Benchmark in gMG Treatment with Landmark Phase 3 Results

Impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®...

April 09, 2025 | Wednesday | News
CareMed Joins Limited Distribution Network for Vanrafia™ (Atrasentan) in Treatment of Primary IgAN

CareMed, an independent specialty pharmacy, is in the Limited Distribution Network for Vanrafia™ (atrasentan), for the reduction of proteinuria ...

April 08, 2025 | Tuesday | News
Halozyme’s ENHANZE® Technology Powers European Approval of Subcutaneous RYBREVANT® for Advanced NSCLC Treatment

 Halozyme Therapeutics, Inc.announced that Janssen-Cilag International NV, a Johnson & Johnson company, has received European Commission (EC) mark...

April 08, 2025 | Tuesday | News
NeuroSense Therapeutics to Present Promising Phase 2b Data for ALS Treatment PrimeC at 77th Annual AAN Meeting

NeuroSense Therapeutics, a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, announced t...

April 07, 2025 | Monday | News
Keymed Biosciences' IL-4Rα Antibody Stapokibart Shows Promising Results in Phase III Trial for Seasonal Allergic Rhinitis

Keymed Biosciences Inc. announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its ...

April 07, 2025 | Monday | News
Rhythm Pharmaceuticals to Announce Topline Results from Phase 3 TRANSCEND Trial of Setmelanotide in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc., a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendoc...

April 07, 2025 | Monday | News
NetraMark and Worldwide Clinical Trials Partner to Advance AI-Driven Precision in Global Clinical Trials

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company th...

April 04, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close